Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Wegener Polyangiitis Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Wegener Polyangiitis Overview | 7 | 1 |
| Wegener Polyangiitis Therapeutics under Development by Companies | 8 | 1 |
| Wegener Polyangiitis Pipeline Products Glance | 9 | 4 |
| Late Stage Products | 9 | 1 |
| Clinical Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Unknown Stage Products | 12 | 1 |
| Wegener Polyangiitis Products under Development by Companies | 13 | 1 |
| Wegener Polyangiitis Companies Involved in Therapeutics Development | 14 | 9 |
| Bionovis SA | 14 | 1 |
| Bristol-Myers Squibb Company | 15 | 1 |
| ChemoCentryx, Inc. | 16 | 1 |
| Coherus BioSciences, Inc. | 17 | 1 |
| Genor BioPharma Co., Ltd. | 18 | 1 |
| GlaxoSmithKline Plc | 19 | 1 |
| Panacea Biotec Limited | 20 | 1 |
| Sandoz International GmbH | 21 | 1 |
| The International Biotechnology Center (IBC) Generium | 22 | 1 |
| Wegener Polyangiitis Therapeutics Assessment | 23 | 9 |
| Assessment by Monotherapy Products | 23 | 1 |
| Assessment by Target | 24 | 2 |
| Assessment by Mechanism of Action | 26 | 2 |
| Assessment by Route of Administration | 28 | 2 |
| Assessment by Molecule Type | 30 | 2 |
| Drug Profiles | 32 | 24 |
| abatacept Drug Profile | 32 | 5 |
| belimumab Drug Profile | 37 | 6 |
| CCX-168 Drug Profile | 43 | 5 |
| rituximab biosimilar Drug Profile | 48 | 2 |
| rituximab biosimilar Drug Profile | 50 | 1 |
| rituximab biosimilar Drug Profile | 51 | 1 |
| rituximab biosimilar Drug Profile | 52 | 1 |
| rituximab biosimilar Drug Profile | 53 | 1 |
| rituximab biosimilar Drug Profile | 54 | 1 |
| rituximab biosimilar Drug Profile | 55 | 1 |
| Wegener Polyangiitis Dormant Projects | 56 | 1 |
| Wegener Polyangiitis Discontinued Products | 57 | 1 |
| Wegener Polyangiitis Product Development Milestones | 58 | 1 |
| Featured News &Press Releases | 58 | 1 |
| Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vascul... | 58 | 1 |
| Appendix | 59 | 2 |
| Methodology | 59 | 1 |
| Coverage | 59 | 1 |
| Secondary Research | 59 | 1 |
| Primary Research | 59 | 1 |
| Expert Panel Validation | 59 | 1 |
| Contact Us | 59 | 1 |
| Disclaimer | 60 | 1 |